NCT04639271: Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis

NCT04639271
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Therapeutic antibody, Tyrosine-Kinase inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with HER2+ breast cancer who have received prior therapy of anti-HER2 tyrosine-kinase inhibitors (e.g. pyrotinib, neratinib, lapatinib, tucatinib). Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT04639271

Comments are closed.

Up ↑